Sailong Pharmaceutical GroupLtd (SZSE:002898) Swells 27% This Week, Taking Three-year Gains to 45%
Sailong Pharmaceutical GroupLtd (SZSE:002898) Swells 27% This Week, Taking Three-year Gains to 45%
Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) shareholders might be concerned after seeing the share price drop 11% in the last quarter. But don't let that distract from the very nice return generated over three years. After all, the share price is up a market-beating 45% in that time.
賽龍藥業集團有限公司, Ltd.(深圳證券交易所:002898)股東在看到上個季度股價下跌11%後可能會感到擔憂。但是,不要讓這分散人們對三年來產生的非常可觀的回報的注意力。畢竟,在那段時間內,股價上漲了超過市場的45%。
Since the stock has added CN¥461m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.
由於該股僅在過去一週就增加了4.61億元人民幣,因此讓我們看看基礎表現是否推動了長期回報。
Given that Sailong Pharmaceutical GroupLtd didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
鑑於賽龍製藥集團有限公司在過去十二個月中沒有盈利,我們將專注於收入增長,以快速了解其業務發展。當一家公司沒有盈利時,我們通常預計收入會有良好的增長。可以想象,收入的快速增長如果持續下去,通常會帶來利潤的快速增長。
Sailong Pharmaceutical GroupLtd's revenue trended up 23% each year over three years. That's much better than most loss-making companies. The share price rise of 13% per year throughout that time is nice to see, and given the revenue growth, that gain seems somewhat justified. If that's the case, now might be the time to take a close look at Sailong Pharmaceutical GroupLtd. If the company is trending towards profitability then it could be very interesting.
賽龍製藥集團有限公司的收入在三年內每年增長23%。這比大多數虧損的公司要好得多。在此期間,股價每年上漲13%,這令人欣慰,考慮到收入的增長,這種增長似乎有些合理。如果是這樣的話,現在可能是仔細研究賽龍製藥集團有限公司的時候了。如果公司傾向於盈利,那可能會很有趣。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以在下面看到收入和收入如何隨着時間的推移而變化(點擊圖片了解確切的值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240316/0-60f37394d656be9577cbe280f578708a-0-5d7854ab207a3ebb1d4f6f249fcac4b1.png/big)
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
您可以在這張免費的交互式圖片中看到其資產負債表如何隨着時間的推移而增強(或減弱)。
A Different Perspective
不同的視角
We're pleased to report that Sailong Pharmaceutical GroupLtd shareholders have received a total shareholder return of 12% over one year. There's no doubt those recent returns are much better than the TSR loss of 3% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Sailong Pharmaceutical GroupLtd .
我們很高興地報告,賽龍製藥集團有限公司的股東在一年內獲得了12%的總股東回報率。毫無疑問,最近的回報遠好於五年內每年3%的股東總回報率損失。長期虧損使我們保持謹慎,但短期股東總回報率的增長無疑暗示着更光明的未來。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。爲此,你應該注意我們在賽龍製藥集團有限公司發現的1個警告信號。
We will like Sailong Pharmaceutical GroupLtd better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我們看到一些重大的內幕收購,我們會更喜歡賽龍藥業集團有限公司。在我們等待的同時,請查看這份免費清單,列出了最近有大量內幕收購的成長型公司。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。